These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9487235)

  • 21. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
    Chrisp P; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
    Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
    Brandle M; Davidson MB; Schriger DL; Lorber B; Herman WH
    Diabetes Care; 2003 Jun; 26(6):1796-801. PubMed ID: 12766112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice.
    Oster G; Borok GM; Menzin J; Heyse JF; Epstein RS; Quinn V; Benson V; Dudl RJ; Epstein AM
    Arch Intern Med; 1996 Apr; 156(7):731-9. PubMed ID: 8615705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
    Smart AJ; Walters L
    S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
    Hay JW; Wittels EH; Gotto AM
    Am J Cardiol; 1991 Apr; 67(9):789-96. PubMed ID: 1901436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
    Sato S; Matsushita Y; Kobayashi T; Awata N
    Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.
    Plans-Rubió P
    Pharmacoeconomics; 2004; 22(1):55-69. PubMed ID: 14720082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.